Tumour antigen-loaded mouse dendritic cells maturing in the presence of inflammatory cytokines are potent activators of immune response in vitro but not in vivo

Oncology Reports

Volumn 21, Issue 6, 2009, Pages 1539-1549

  Rossowska, Joanna ^a   Pajtasz Piasecka, Elzbieta ^a   Szyda, Anna ^a   Krawczenko, Agnieszka ^a   Zietara, Natalia ^a   Dus, Danuta ^a  

^a INSTITUTE OF IMMUNOLOGY AND EXPERIMENTAL THERAPY   (Poland)

Author keywords

CD107a molecules; IFN production; IL 12 transduced BM DC; Inflammatory cytokines; Murine colon carcinoma MC38; T cell cytotoxicity; Tumour antigen loaded dendritic cells

Indexed keywords

B7 ANTIGEN; CD40 ANTIGEN; CD86 ANTIGEN; CYTOKINE; DENDRITIC CELL VACCINE; GAMMA INTERFERON; INTERLEUKIN 12; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; RETROVIRUS VECTOR; TUMOR ANTIGEN; TUMOR NECROSIS FACTOR ALPHA; AUTACOID; CANCER VACCINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CD8+ T LYMPHOCYTE; CELL DIFFERENTIATION; CELL LYSATE; CELL MATURATION; CELL MEDIATED CYTOTOXICITY; CELLULAR IMMUNITY; CONTROLLED STUDY; CYTOKINE PRODUCTION; FEMALE; HUMAN; IN VITRO GENE TRANSFER; IN VIVO GENE TRANSFER; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; T LYMPHOCYTE ACTIVATION; ADOPTIVE IMMUNOTHERAPY; ANIMAL; C57BL MOUSE; CELL CULTURE; COLON TUMOR; DENDRITIC CELL; GENETIC TRANSDUCTION; GENETICS; IMMUNOLOGY; LYMPHOCYTE ACTIVATION; METABOLISM; SPLEEN; TH1 CELL; TH2 CELL; TIME; TRANSPLANTATION; TUMOR CELL LINE;

ANIMALS; ANTIGENS, NEOPLASM; CANCER VACCINES; CELL DIFFERENTIATION; CELL LINE, TUMOR; CELLS, CULTURED; COLONIC NEOPLASMS; CYTOKINES; DENDRITIC CELLS; FEMALE; IMMUNOTHERAPY, ADOPTIVE; INFLAMMATION MEDIATORS; INTERFERON-GAMMA; INTERLEUKIN-12; LYMPHOCYTE ACTIVATION; MICE; MICE, INBRED C57BL; SPLEEN; TH1 CELLS; TH2 CELLS; TIME FACTORS; TRANSDUCTION, GENETIC; TUMOR NECROSIS FACTOR-ALPHA;

EID: 67649947499     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or_00000386     Document Type: Article

References (28)

1. Abbas AK and Sharpe AH: Dendritic cells giveth and taketh away. Nat Immunol 6: 227-228, 2005.
2. Byrne S and Halliday G: Dendritic cells: making progress with tumour regression? Immunol Cell Biol 80: 520-530, 2002.
3. Yoshida S, Morii K, Watanabe M, Saito T, Yamamoto K and Tanaka R: The generation of anti-tumoural cells using dentritic cells from the peripheral blood of patients with malignant brain tumours. Cancer Immunol Immunother 50: 321-327, 2001.
4. Iwashita Y, Tahara K, Goto S, et al: A phase I study of autologous dendritic cell-based immunotherapy for patients with unresectable primary liver cancer. Cancer Immunol Immunother 52: 155-161, 2003.
5. Kondo H, Hazama S, Kawaoka T, et al: Adoptive immunotherapy for pancreatic cancer using MUC1 peptide-pulsed dendritic cells and activated T lymphocytes. Anticancer Res 28: 379-387, 2008.
6. Guardino AE, Rajapaksa R, Ong KH, Sheehan K and Levy R: Production of myeloid dendritic cells (DC) pulsed with tumourspecific idiotype protein for vaccination of patients with multiple myeloma. Cytotherapy 8: 277-289, 2006.
7. Kobayashi T, Yamanaka R, Homma J, et al: Tumour mRNA-loaded dendritic cells elicit tumour-specific CD8(+) cytotoxic T cells in patients with malignant glioma. Cancer Immunol Immunother 52: 632-637, 2003.
8. Manickan E, Kanangat S, Rouse RJ, Yu Z and Rouse BT: Enhancement of immune response to naked DNA vaccine by immunization with transfected dendritic cells. J Leukocyte Biol 61: 125-132, 1997.
9. + T cells engaging class II molecules in cholesterol-rich domains. J Immunol 168: 1172-1180, 2002.
10. Nouri-Shirazi M, Banchereau J, Bell D, et al: Dendritic cells capture killed tumour cells and present their antigens to elicit tumour-specific immune responses. J Immunol 165: 3797-3803, 2000.
11. Chen Z, Moyana T, Saxena A, Warrington R, Jia Z and Xiang J: Efficient antitumour immunity derived from maturation of dendritic cells that had phagocytosed apoptotic/necrotic tumour cells. Int J Cancer 93: 539-548, 2001.
12. Vegh Z and Mazumder A: Generation of tumour cell lysateloaded dendritic cells preprogrammed for IL-12 production and augmented T cell response. Cancer Immunol Immunother 52: 67-79, 2003.
13. Kaka AS, Foster AE, Weiss HL, Rooney CM and Leen AM: Using dendritic cell maturation and IL-12 producing capacity as markers of function: a cautionary tale. J Immunother 31: 359-369, 2008.
14. Mellman I and Steinman RM: Dendritic cells: specialized and regulated antigen processing machines. Cell 106: 255-258, 2001.
15. Menges M, Rößner S, Voigtländer C, et al: Repetitive injections of dendritic cells matured with tumour necrosis factor α induce antigen-specific protection of mice from autoimmunity. J Exp Med 195: 15-21, 2002.
16. Kelleher P and Knight SC: IL-12 increases CD80 expression and the stimulatory capacity of bone marrow-derived dendritic cells. Int Immunol 10: 749-755, 1998.
17. Eskelinen EL, Tanaka Y and Saftig P: At the acidic edge: emerging functions for lysosomal membrane proteins. Trends Cell Biol 13: 137-145, 2003.
18. Alter G, Malenfant JM and Altfeld M: CD107a as a functional marker for the identification of natural killer cell activity. J Immunol Methods 294: 15-22, 2004.
19. Betts MR and Koup RA: Detection of T-cell degranulation: CD107a and b. Methods Cell Biol 75: 497-512, 2004.
20. He XZ, Wang L and Zhang YY: An effective vaccine against colon cancer in mice: use of recombinant adenovirus interleukin-12 transduced dendritic cells. World J Gastroenterol 14: 532-540, 2008.
21. Pajtasz-Piasecka E, Szyda A, Rossowska J, et al: Loss of tumourigenicity of murine colon carcinoma MC38/0 cell line after transduction with a retroviral vector carrying murine IL-12 genes. Folia Biol (Praha) 50: 7-14, 2004.
22. Pajtasz-Piasecka E, Rossowska J, Szyda A, Krawczenko A and Dus D: Generation of anti-tumour response by JAWS II mouse dendritic cells transduced with murine interleukin 12 genes. Oncol Rep 17: 1249-1257, 2007.
23. Spisek R, Bougras G, Ebstein F, Masse D, Meflah K, McIlroy D and Gregoire M: Transient exposure of dendritic cells to maturation stimuli is sufficient to induce complete phenotypic maturation while preserving their capacity to respond to subsequent restimulation. Cancer Immunol Immunother 52: 445-454, 2003.
24. Langenkamp A, Messi M, Lanzavecchia A and Sallusto F: Kinetics of dendritic cell activation: impact on priming of Th1, Th2 and nonpolarized T cells. Nat Immunol 1: 311-316, 2000.
25. Woo SC, Kim GY, Lee CM, et al: The maturation of murine bone marrow-derived dendritic cells by tumour lysate uptake in vitro is not essential for cancer immunotherapy. Cancer Biol Ther 4: 1331-1335, 2005.
26. Rossowska J, Pajtasz-Piasecka E, Szyda A, Zietara A and Dus D: Tissue localization of tumour antigen-loaded mouse dendritic cells applied as an anti-tumour vaccine and their influence on immune response. Folia Histochem Cytobiol 4: 349-355, 2007.
27. Mullins DW and Engelhard VH: Limited infiltration of exogenous dendritic cells and naive T cells restricts immune responses in peripheral lymph nodes. J Immunol 176: 4535-4542, 2006.
28. Mocellin S, Wang E and Marincola FM: Cytokines and immune response in the tumour microenvironment. J Immunother 24: 392-407, 2001.